Thank you for your patience while your manuscript has been reviewed. We have just now received the full set of reports from the referees, which I copy below. As you will see from their reports, they agree in the high interest of your study and their comments are therefore rather positive.
In brief, all referees agree in the interest and novelty of your work, especially referees #1 and #2, who nevertheless believe that some technical issues should be solved and certain misunderstandings in the figures disambiguated before the article is ready for publication. Referee #3, although still positive, considers that the conceptual novelty of the study is partially compromised by previous reports already linking Hsp90 and ILK, although arguably these earlier findings do not functionally explore this interaction. However, other functional interactions have been shown between FAK and Hsp90 and referee #3 considers that it is important to discriminate whether the effects observed are mainly caused through ILK, or other components such as FAK could also be involved. S/he also points out to the fact that the link to fibrosis in vivo is not sufficiently developed from a mechanistic perspective. While obviously interesting, I believe that it would be out of the scope of this work to further pursue this point. That being said, if you already have data in hand that could improve the manuscript along these lines, it would only be in your best interest to include it, although it will not be determinant for the acceptance of your study.
I would therefore like to invite you to submit a revised version of the manuscript. Please be aware that your revised manuscript must address the referees' concerns. I would also like to remind you that it is 'The EMBO Journal' policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process iniciative, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you again for the opportunity to consider your work for publication. I look forward to your revision.
Please, do no hesitate to contact me in case you have any further question, need further input or any problem arises during the revision process.
REFEREE REPORTS:
Referee #1:
Radovanac and colleagues investigate the impact of the Hsp90 chaperone system on the activity and stability of the integrin-linked kinase ILK, which is a cytoskeleton adaptor protein essential for cell adhesion and for remodeling of the extracellular matrix (ECM). The authors provide evidence that the Hsp90-associated ubiquitin ligase CHIP targets ILK for proteasomal degradation. Association with Hsp90 seems to be necessary for the stabilization of the kinase-like domain of ILK and seems to facilitate association of ILK with certain partner proteins. Consistent with a role of Hsp90 in regulating ILK activity the authors observe that pharmacologic inhibition of Hsp90 impairs fibroblast migration and attenuates fibrotic responses in mice. The findings are interesting and of relevance. However, some conclusions are not well supported by the presented experimental data and additional controls need to be added.
1. Figure 1A : Size standards should be added. 2. Figure 1B: The different blots should be separated. Size standards should be added -so that the reader can judge whether prominent signals in the blots are of the same size. The high molecular mass region of the ILK blot should be shown -in order to evaluate whether indeed a significant fraction of ILK forms high molecular mass ubiquitin conjugates. 3. Figure 2 : The amino-terminal portion of CHIP contains multiple tetratricopeptide repeats, which are usually abbreviated as "TPR" motifs -instead of "TRP" as used by Radovanac et al. throughout their study. The authors should correct this. 4. Figure 2D : It would be helpful if the authors could change the labelling in the presented figures to indicate which protein was tagged for affinity purification and complex isolation, i.e. changing "CHIP" on the right of this figure to "EGFP-CHIP" would clarify which protein was used for pulldown. 5. On a similar note as point 4: changing "CHIP" on the right of Figure 2E to "His-CHIP" would clarify things. 6. All co-precipitation data rely on the overexpression of at least one binding partner. The authors should verify CHIP-ILK interaction for endogenous proteins by immunoprecipitation or related techniques. (Partial co-localization of endogenous components in focal contacts observed by fluorescence microscopy -presented in Figure 4A -does not necessarily reflect an interaction between CHIP and ILK). 7. Figure 3A : Size standards need to be added here and unmodified ILK should be pointed out. If ILK is the lowest band on the blot, the question arises why so much less protein is loaded/detectable in lane 1. 8. Figure 3C : Again, size standards are required for evaluating how conjugate signals correlate in the anti-ubiquitin and anti-ILK blot. 9. Figure 3C : It is surprising that CHIP overexpression (lane 6) actually increases the ILK signal in the input. This seems to contradict the authors' conclusion regarding CHIP-mediated degradation of ILK. If proteasome inhibitors were used in this experiment it should be clearly stated in the figure legend. 10. Figure 4B : It needs to be clarified in the legend what the time points refer to. 11. Figure 4B : The authors deduce from this figure the following: "the assay also revealed that at early stages of spreading (30 min) CHIP was absent from small, immature adhesions containing paxillin but lacking a linkage to F-actin stress fibers. (Fig. 4B) . The colocalization of CHIP with F-actin stress fibers suggests that CHIP might bind F-actin." Both conclusions appear to be little supported by the presented low resolution and low magnification pictures. It seems that there is actually a pretty good overlap between CHIP and Paxillin at 30 min. Immature adhesions cannot be readily identified by the reader. Higher magnification pictures would be required. A colocalization of CHIP along actin stress fibers is not deducible at 120 min. 12. Figure 4C : The co-sedimentation data are not convincing. The Material and Methods section states that 3mM CHIP was used in this experiment. This is probably a typing error and should read 3µM. Only a fraction of the added CHIP co-sediments with actin when the latter is used at the highest concentration of 20µM. The relevance of this weak interaction remains to be determined (in particular because also the co-localization data in Figure 4B are not convincing). 13. Figure 5A -G: It is difficult to deduce the extent of ILK degradation from blots from single experiments. The authors should repeat degradation assays multiple times, should normalize values against control protein levels (e.g. GAPDH) and present mean values with standard deviation. 14. Figure 5F : Rather than presenting steady state protein levels at different concentrations of 17-AAG, the authors should deduce turnover rates of ILK in control and CHIP-deficient cells treated with cycloheximide. This should be done in the absence and presence of 17-AAG (multiple experiments presented with standard deviation). Although Hsp90 inhibition may trigger CHIPmediated degradation of ILK it remains to be verified whether CHIP normally participates in ILK degradation. 15. Figure 6E : Because ILK deficiency on its own strongly impairs cell migration it is not too surprising that 17-AAG treatment does not have an additional effect. This does not show, however, "that the effect of 17AAG is mediated by the activity of Hsp90 towards ILK".
16. Discussion: "we identified CHIP as the E3 ligase inducing K48-linked poly-ubiquitin chains on ILK, which in turn triggers proteasomal degradation." This is too strong a statement. It is not shown that CHIP is the key player in this regard under normal growth conditions. ILK ubiquitylation and degradation needs to be monitored in CHIP-deficient cells without inhibiting Hsp90 activity.
Referee #2:
The manuscript by Radovanac et al. follows previous work on the regulation of the integrin-actin linkage by some of the authors, including the specific role of the integrin-linked kinase (ILK). The present study focuses on the role of Hsp90-CHIP in the assembly and stability regulation of the ILK-pinch-parvin (IPP) complex. Mass spectrometry and biochemical analyses identified the CHIPHsp90-Hsc70 chaperone machinery as novel interaction partners of ILK. The authors observed, that ILK is polyubiquitinated by the E3 ligase CHIP, which leads to its proteasomal degradation. Furthermore, the authors show that the stabilization of ILK by Hsp90 is required for the interaction of ILK with alpha-parvin, thereby promoting cellular force generation and cell migration. Inhibition of Hsp90 activity in vivo resulted in the attenuation of bleomycin-induced skin fibrosis in mice. This work is a thorough study that uses a broad spectrum of state-of-the-art techniques to explore the molecular mechanisms by which the stability of ILK and the IPP complex are regulated by the Hsp90-CHIP axis. Overall the data are clearly presented and the findings are likely to be of quite broad interest.
Major comments: 1) Numerous confocal immunofluorescent images are of poor quality, especially those in which the authors intend to highlight differences in subcellular localization of proteins or small structures, e.g. small, immature adhesions in Figure 4B . It is necessary to have images with higher magnification and better resolution. 2) Figure 4A : The authors observed that CHIP is partly co-localized with ILK in focal adhesions. Furthermore, they conclude that this localization is independent of ILK as they found a similar CHIP localization in ILK-/-cells. However, in order to conclude that CHIP is localized in focal adhesions in ILK-/-cells the authors need to show this in colocalization studies with CHIP together with established focal adhesion markers (e.g. talin or vinculin). Figure 2B might be important enough to be in the paper. 5) Figure 6C : The authors should explain in more deatil how the "Relative FA area" was calculated. 6) Figure 6D : Interestingly, inhibition of HSP90 activity abrogates contraction of fibroblasts in collagen gels. By calculating the gel diameter the authors used a rude assay, which shows impressively the overall contraction cabability of all cells. It could be usefull to perform further assays on a single cell level, e.g. visualization and quantification of fluorescent beads displacements in the vicinity of individual cells (see Legant et al., Nature Methods, 2010) . This technique allows to reveal patterns of force generation attributable to morphologically distinct regions of cells as they extend into the surrounding matrix. 7) Figure The study submitted by Radovanac and co-workers describe an interesting mechanism linking ubiquitination and degradation of ILK to focal adhesion modulation, contractility and fibrosis. They show using state-of-the-art mass-spec that ILK is strongly ubiquitinated and identify Hsc70, Hsp90 and CHIP in complex with ILK. They go on to show that this complex exists in cells and HSP90 regulates ILK stability via controlling the recruitment of CHIP to ILK. In cells inhibition of HSP90 with a drug (17AAG) induces loss of ILK from focal adhesions and induces a change in focal adhesion architecture, collagen gel contraction and cell migration in collagen. In vivo in mice, 17AAG treatment inhibits bleomycin-induced fibrosis. This is an interesting study and it provides important functional insight into the observed presence of ubiquitin and chaperones like HSP90 in adhesion complexes (reported by comprehensive mass-spec studies). Unfortunately the novelty of some of the data is compromised by the fact that Hsp90 has already been shown to interact with ILK via the kinase-like-domain (as shown here in Fig. 2A ) and the ability of Hsp90 to stabilize ILK and protect it from proteosomal degradation is also demonstrated in the same study (Aoyagi et al., 2005 , which is cited by the authors). This earlier study also demonstrates that FAK (and some other integrin signalling related kinases) are also regulated by Hsp90 and 17AAG inhibits FAK stability significantly. The authors have not investigated FAK here. However, since FAK is an important regulator of focal adhesion turnover, cell migration and contractility it is important to address how much of the observed 17AAG effects are really due to ILK loss. The authors are using the ILK-/-cells as controls and this is convincing but since these cells have smaller focal adhesions (Sakai et al., 2003) the FAK function may be compromised in these cells already and the effects in the ILK-expressing cells are due to downregulation of ILK and FAK. This needs to be carefully addressed.
The link to fibrosis is interesting and clinically relevant but the mechanism is totally unclear. The authors should investigate whether matrix production, matrix assembly or proteolytic activity are dependent on ILK and ILK stabilization by Hsp90.
In general the biochemistry of the paper is well done, but the imaging could be improved. Also it is not clear whether the western blots for example in figure 5 are done only once or representatives of several experiments. Quantification of the data from different experiments would increase the impact of these findings. Referee #1:
1. Figure 1A : Size standards should be added.
Size standards have been added.
2. Figure 1B : The different blots should be separated. Size standards should be added -so that the reader can judge whether prominent signals in the blots are of the same size. The high molecular mass region of the ILK blot should be shown -in order to evaluate whether indeed a significant fraction of ILK forms high molecular mass ubiquitin conjugates. Size standards have been added, the blots have been more clearly separated and the complete ILK blot is shown.
Figure 2:
The amino-terminal portion of CHIP contains multiple tetratricopeptide repeats, which are usually abbreviated as "TPR" motifs -instead of "TRP" as used by Radovanac et al. throughout their study. The authors should correct this. The abbreviation has been corrected throughout. We thank the reviewer for pointing this out.
4. Figure 2D : It would be helpful if the authors could change the labelling in the presented figures to indicate which protein was tagged for affinity purification and complex isolation, i.e. changing "CHIP" on the right of this figure to "EGFP-CHIP" would clarify which protein was used for pulldown.
The labelling has been changed (Fig. 2E in revised manuscript).
5. On a similar note as point 4: changing "CHIP" on the right of Figure 2E to "His-CHIP" would clarify things. The labelling has been changed ( Fig. 2F in revised manuscript) .
6. All co-precipitation data rely on the overexpression of at least one binding partner. The authors should verify CHIP-ILK interaction for endogenous proteins by immunoprecipitation or related techniques. (Partial co-localization of endogenous components in focal contacts observed by fluorescence microscopy -presented in Figure 4A - 11. Figure 4B : The authors deduce from this figure the following: "the assay also revealed that at early stages of spreading (30 min) CHIP was absent from small, immature adhesions containing paxillin but lacking a linkage to F-actin stress fibers. (Fig. 4B) . The colocalization of CHIP with F-actin stress fibers suggests that CHIP might bind F-actin." Both conclusions appear to be little supported by the presented low resolution and low magnification pictures. It seems that there is actually a pretty good overlap between CHIP and Paxillin at 30 min. Immature adhesions cannot be readily identified by the reader. Higher magnification pictures would be required. A colocalization of CHIP along actin stress fibers is not deducible at 120 min.
We agree that immature adhesions were difficult to see in the Fig. 4B of the initial manuscript. The low resolution was unfortunately in part due to the compression of the pdf file to conform to file size limits of the submission platform. We have now replaced Fig. 4B with better quality images and included blow ups to better highlight our results.
12. Figure 4C : The co-sedimentation data are not convincing. The Material and Methods section states that 3mM CHIP was used in this experiment. This is probably a typing error and should read 3µM. Only a fraction of the added CHIP co-sediments with actin when the latter is used at the highest concentration of 20µM. The relevance of this weak interaction remains to be determined (in particular because also the co-localization data in Figure 4B are not convincing).
We thank the reviewer for pointing out the typing error. We agree that the affinity of CHIP to actin is relatively weak and probably points out to an indirect association with polymerized actin. We therefore removed this data from the manuscript.
13. Figure 5A -G: It is difficult to deduce the extent of ILK degradation from blots from single experiments. The authors should repeat degradation assays multiple times, should normalize values against control protein levels (e.g. GAPDH) and present mean values with standard deviation.
We have naturally repeated all experiments multiple times in the course of these studies and present representative images of these repetitions in the manuscript. As suggested we have included quantifications of multiple western blots from all degradation assays in this figure.
14. Figure 5F : Rather than presenting steady state protein levels at different concentrations of 17-AAG, the authors should deduce turnover rates of ILK in control and CHIP-deficient cells treated with cycloheximide. This should be done in the absence and presence of 17-AAG (multiple experiments presented with standard deviation). Although Hsp90 inhibition may trigger CHIPmediated degradation of ILK it remains to be verified whether CHIP normally participates in ILK degradation. Referee #2:
These are excellent suggestions. We have performed additional experiments in CHIP-deficient cells where we have analysed turnover rates of ILK using cycloheximide. These experiments show that CHIP does not regulate basal turnover of ILK and is thus specifically involved in degrading unstabilized ILK when Hsp90 is inhibited. This data has been quantified and is presented in the new
Major comments:
1) Numerous confocal immunofluorescent images are of poor quality, especially those in which the authors intend to highlight differences in subcellular localization of proteins or small structures, e.g. small, immature adhesions in Figure 4B . It is necessary to have images with higher magnification and better resolution.
We apologize for the poor resolution of the immunofluorescence images, particularly in Fig. 4B of the initial manuscript. The low resolution was unfortunately in part due to the compression of the pdf file to conform to file size limits of the submission platform. We have now increased the resolution and replaced Fig. 4B with better quality images and included blow ups to better highlight our results.
2) Figure 4A : The authors observed that CHIP is partly co-localized with ILK in focal adhesions. Furthermore, they conclude that this localization is independent of ILK as they found a similar CHIP localization in ILK-/-cells. However, in order to conclude that CHIP is localized in focal adhesions in ILK-/-cells the authors need to show this in colocalization studies with CHIP together with established focal adhesion markers (e.g. talin or vinculin). Supplementary Fig. 1 ) to strengthen this point.
We have now included additional stainings of CHIP together with the established focal adhesion marker paxillin in ILK -/-cells (new
Furthermore the authors should comment on the result, that in ILK-/-cells stress fibers are absent and that the cells do not spread and show a different cell morphology as compared to ILK f/f cells.
We have modified the text on p.10 to emphasize this point.
3) Figure 4A and Supporting Figure 1: The authors conclude that endogenous CHIP as well as EGFP-CHIP colocalizes with F-Actin stress fibers. To conclude this the authors need to show a costaining of CHIP with fluorochrome-labelled Phalloidin.
We now show co-staining of CHIP with phalloidin in Figure 4A and Supplementary Fig. 1 ( Supplementary Fig. 2 in revised manuscript) . Figure 2B might be important enough to be in the paper. Fig. 2B to Fig. 6C . Figure 6C : The authors should explain in more detail how the "Relative FA area" was calculated.
4) Supporting Information

We have moved Supplementary Information
5)
We have now included a more detailed description of this analysis in the Materials and methods section. Figure 6D : Interestingly, inhibition of HSP90 activity abrogates contraction of fibroblasts in collagen gels. By calculating the gel diameter the authors used a rude assay, which shows impressively the overall contraction capability of all cells. It could be useful to perform further assays on a single cell level, e.g. visualization and quantification of fluorescent beads displacements in the vicinity of individual cells (see Legant et al., Nature Methods, 2010) . This technique allows to reveal patterns of force generation attributable to morphologically distinct regions of cells as they extend into the surrounding matrix.
6)
As suggested we have now performed traction force microscopy to quantitatively analyse forces exerted by single cells on the extracellular matrix. These analysis show that ILK plays a central role in cellular force generation as ILK -/-cells show significantly lower force magnitudes. In addition, 17AAG treatment decreases cellular force generation in wild type cells, whereas no significant effect is seen in 17AAG-treated ILK -/-cells (new Figs 7B, C).
7) Figure 6E : What is the time frame (duration) of the cell migration assays? Is the cell morphology of migrating ILK-/-fibroblasts and 17AAG-treated ILK f/f fibroblasts different as compared to wildtype control cells?
The 3D migration experiments were imaged for 20 h with a 1 min frame rate. We have added this information in the Materials and methods section. The morphology of the ILK f/f cells treated with 17AAG differed from the wild type control cells in a manner very similar to the observations made in the immunofluorescence analysis in Fig 5. The 17AAG-treated cells displayed a more elongated shape and displayed reduced lamellipodial dynamics, whereas ILK -/-cells appear more rounded. We have included live cell imaging data from the 3D migration assays as Supplementary Movies 2-4.
Minor comment:
1) Figure 4 : The labelling of the "FLAG pull-down" in the figure legend needs to be corrected in 4"E". This has been corrected (Fig. 4C in the revised manuscript) .
This is an interesting study and it provides important functional insight into the observed presence of ubiquitin and chaperones like HSP90 in adhesion complexes (reported by comprehensive mass-spec studies). Unfortunately the novelty of some of the data is compromised by the fact that Hsp90 has already been shown to interact with ILK via the kinase-like-domain (as shown here in Fig. 2A ) and the ability of Hsp90 to stabilize ILK and protect it from proteosomal degradation is also demonstrated in the same study (Aoyagi et al., 2005 , which is cited by the authors). This earlier study also demonstrates that FAK (and some other integrin signalling related kinases) are also regulated by Hsp90 and 17AAG inhibits FAK stability significantly. The authors have not investigated FAK here. However, since FAK is an important regulator of focal adhesion turnover, cell migration and contractility it is important to address how much of the observed 17AAG effects are really due to ILK loss. The authors are using the ILK-/-cells as controls and this is convincing but since these cells have smaller focal adhesions (Sakai et al., 2003) Supplementary Fig. 4 ). Fig. 8D .
In general the biochemistry of the paper is well done, but the imaging could be improved. Also it is not clear whether the western blots for example in figure 5 Thank you for the submission of the revised version of your manuscript entitled "Stabilization of ILK by the Hsp90-CHIP axis impacts force generation, migration and fibrosis". It has been sent to two of the original reviewers, who now consider that your study is basically ready for publication, pending some very minor revisions (mostly some suggested rephrasing, see comments pasted below). I am therefore writing with an 'accept in principle' decision, which means that I will be happy to accept your manuscript for publication once these few details have been addressed.
I would also like to mention that, as a novel initiative in The EMBO Journal, we now encourage the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Although optional at the moment, would you be willing to provide a PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figures? The PDF files should be labeled with the appropriate figure/panel number, and should have molecular weight markers; further annotation could be useful but is not essential. The files will be published online with the article as supplementary "Source Data" files. If you have any questions regarding this initiative do not hesitate to contact me.
Thank you very much for your patience and congratulations in advance on a successful publication. Once these minor changes suggested by referee #1 are incorporated into the manuscript, you will receive an official acceptance letter with further instructions on how to proceed with the publication process.
REFEREE REPORTS:
The revised manuscript represents a considerable improvement. Major concerns were addressed. Yet, the observation that CHIP is not involved in ILK degradation under physiological conditions ( Figure 5K and L) weakens the significance of the study. The possibility remains that the used CHIP-deficient cells are not suitable to verify an involvement of CHIP in ILK degradation under physiological conditions. There is a considerable overlap in substrate specificity among ubiquitin ligases, and the CHIP-/-cells may therefore adopt by inducing the expression of other ubiquitin ligases. A transient siRNA-mediated depletion of CHIP might give other results and might be worth testing.
In the absence of such data, the authors should certainly rephrase parts of the manuscript. For example:
Title: "Stabilization of Integrin-linked kinase by the Hsp90-CHIP axis impacts cellular force generation, migration and the fibrotic response" It is certainly the Hsp90 axis -but not CHIP, which is involved in stabilization of ILK.
Abstract: "Together, our results uncover the molecular regulation of ILK stability (...)" The components that mediate ILK degradation remain to be identified, as CHIP is apparently not involved here.
End of Introduction: "We report that ILK is polyubiquitinated by the E3 ligase CHIP, which leads to its proteasomal degradation." It should be clarified that CHIP is only involved when Hsp90 activity is blocked.
Discussion: "In the present study we show that the turnover of ILK is regulated by the Hsp90-Hsc70-CHIP chaperone -E3 ligase machinery." Again, it should be mentioned that CHIP involvement is only seen following Hsp90 inhibition and that CHIP does not contribute to ILK degradation under physiological conditions.
Referee #3:
The authors have now addressed all the issues and the new FAK data are very interesting. Reviewer #1:
In the absence of such data, the authors should certainly rephrase parts of the manuscript. For example: Title: "Stabilization of Integrin-linked kinase by the Hsp90-CHIP axis impacts cellular force generation, migration and the fibrotic response" It is certainly the Hsp90 axis -but not CHIP, which is involved in stabilization of ILK. 
